# TB Host Directed Therapy

> **NCT02968927** · PHASE2 · UNKNOWN · sponsor: **The Aurum Institute NPC** · enrollment: 200 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Everolimus 0.5 MG
- **DRUG:** Auranofin 6 MG
- **DRUG:** Vitamin D3
- **DRUG:** CC-11050
- **DRUG:** 2HRbZE/4HRb

## Key facts

- **NCT ID:** NCT02968927
- **Lead sponsor:** The Aurum Institute NPC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2018-09
- **Final completion:** 2020-12
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02968927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02968927, "TB Host Directed Therapy". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02968927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*